Literature DB >> 8015087

Nerve sparing retroperitoneal lymphadenectomy after primary chemotherapy for metastatic testicular carcinoma.

G R Wahle1, R S Foster, R Bihrle, R G Rowland, R M Bennett, J P Donohue.   

Abstract

Initial success with nerve sparing retroperitoneal lymph node dissections in patients with low stage nonseminomatous germ cell tumors of the testis has led to the application of these techniques to a select group of 40 patients treated after chemotherapy at our institution between March 1988 and November 1991. A minimum 1-year followup was available for 38 patients. There have been no abdominal relapses, and 34 of the 38 patients report normal ejaculation postoperatively. Nerve sparing techniques are applicable to select patients undergoing retroperitoneal lymph node dissection after primary chemotherapy for metastatic disease without increasing the chance of local recurrence. Emission and ejaculation are preserved in the majority of patients.

Entities:  

Mesh:

Year:  1994        PMID: 8015087     DOI: 10.1016/s0022-5347(17)32755-6

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  5 in total

Review 1.  Secondary surgery in germ cell tumors--when and how extensively should it be performed?

Authors:  Richard S Foster; Stephen Beck; Richard Bihrle
Journal:  World J Urol       Date:  2004-03-30       Impact factor: 4.226

2.  Post-chemotherapy robot-assisted retroperitoneal lymph node dissection in non-seminomatous germ cell tumor of testis: Feasibility and outcomes of initial cases.

Authors:  Ekrem İslamoğlu; Çağatay Özsoy; Hakan Anıl; Yasin Aktaş; Mutlu Ateş; Murat Savaş
Journal:  Turk J Urol       Date:  2018-12-20

3.  Canadian Urological Association consensus guideline: Management of testicular germ cell cancer.

Authors:  Robert J Hamilton; Christina Canil; Noa Shani Shrem; Kopika Kuhathaas; Maria Di Jiang; Peter Chung; Scott North; Piotr Czaykowski; Sebastien Hotte; Eric Winquist; Christian Kollmannsberger; Armen Aprikian; Denis Soulières; Scott Tyldesley; Alan I So; Nicholas Power; Ricardo A Rendon; Martin O'Malley; Lori Wood; Michael A S Jewett
Journal:  Can Urol Assoc J       Date:  2022-06       Impact factor: 2.052

4.  Stage II nonseminomatous germ-cell testicular tumors--the Indiana experience and risk-benefit analysis.

Authors:  R S Foster; R Bihrle; J S Little; R G Rowland; J P Donohue
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

5.  Nerve-Sparing Postchemotherapy Retroperitoneal Lymph Node Dissection (PC RPLND) for Nonseminomatous Germ Cell Tumour: Experience from a Tertiary Cancer Centre.

Authors:  Anand Raja; Kanuj Malik; N Kathiresan; Venkatraman Radhakrishnan
Journal:  Indian J Surg Oncol       Date:  2021-03-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.